新型抗癫痫药卢非酰胺(Rufinamid)的疗效怎么样？

Rufinamid is a new anti-epileptic drug with a novel triazole derivative structure. Research shows that compared with placebo, rufinamid can significantly reduce the total frequency of epileptic seizures and drop seizure frequency in 28 days, and significantly increase the proportion of patients who reduce the number of single seizures by more than 50%.

The severity of epileptic seizures in the

group was significantly improved compared to the placebo group. In a 3-year open-label extension study, reductions in fall seizure frequency and total seizures were maintained in patients with epilepsy.

Rufinamid effectiveness

Rufinamid, a triazole derivative, is an oral anti-epileptic drug approved in the EU as adjuvant therapy for the treatment of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) in patients over 1 year of age.

It is speculated that rufinamide provides its anti-aging activity by prolonging the inactive period of sodium channels and stabilizing cell membranes. It is extensively absorbed and metabolized and then excreted by the kidneys as inactive metabolites.

Clinical trials have shown that adding rufinamide can effectively reduce the frequency of seizures in patients with LGS and refractory partial epilepsy. Rufinamid has no effect on cognitive function in patients with refractory partial-onset seizures.

Analysis of clinical efficacy of Rufinamide

Rufinamid (Rufinamid), as an adjuvant therapy, has significant efficacy in adult patients with epilepsy and patients with epileptic seizures related to Lennox-Gastaut syndrome.

Rufinamid, a triazole derivative structurally unrelated to other antiepileptic drugs, was initially granted orphan drug status, and marketing authorization was obtained on the basis of a randomized, double-blind, placebo-controlled trial in 138 LGS patients.

An open-label extension study subsequently demonstrated that the efficacy and tolerability of rufinamide were maintained over a longer period of time (median treatment duration, 432 days). Recently published reports from Europe and the United States describe the use of adjuvant rufinamide in clinical practice for the treatment of LGS.

In addition, a study investigated the efficacy and safety of rufinamide in 45 children and young adults with refractory partial and generalized seizures/epilepsy. Among these patients, 19 (46%) had a seizure frequency reduction of more than 50% after taking Rufinamid, and 7 patients had a seizure frequency reduction of more than 75%.

Rufinamid (Rufinamid) Safety

Studies have shown that the short-term incidence of rufinamide (Rufinamid) is similar to that of placebo. Safety data from long-term studies show that rufinamide is well tolerated and causes headache, dizziness, and fatigue in >10% of patients.

Rufinamid has few clinically relevant drug interactions, although it increases serum concentrations of phenytoin and sodium valproate increases serum concentrations of rufinamid.

Data show that rufinamide is safe and effective as an adjuvant drug for LGS and can be used to treat partial seizures.

Recommended hot articles: